Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 10, 2005, Pages 2245-2253

  Oldgren, J ^a   Bylock, A ^c   Wallentin, L ^d   Siegbahn, A ^b   Christersson, Christina ^a,b  

^a Department of Cardiology ^*  (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

Author keywords

Activated partial thromboplastin time; Anticoagulants; Coagulation; Direct thrombin inhibitor; Myocardial infarction

Indexed keywords

D DIMER; MELAGATRAN; PROTHROMBIN; THROMBIN INHIBITOR; THROMBOPLASTIN; XIMELAGATRAN;

AGED; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 28444440214     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01557.x     Document Type: Article

References (28)

1. Corti R, Farkouh ME, Badimon JJ. The vulnerable plaque and acute coronary syndromes. Am J Med 2002; 113: 668-80.
2. Reganon E, Vila V, Martinez-Sales V, Vaya A, Aznar J. Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction. Haematologica 2002; 87: 740-5; discussion 745.
3. Antithrombatic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. TV Engl J Med 2001; 345: 494-502.
5. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89.
6. Eikelboom JW, Weitz JI, Budaj A, Zhao F, Copland I, Maciejewski P, Johnston M, Yusuf S. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2002; 23: 1771-9.
7. FRISC II Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during Instability in Coronary artery disease. Lancet 1999; 354: 701-7.
8. FRISC Study Group. Low-molecular-weight heparin during instability in coronary artery disease, fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996; 347: 561-8.
9. Ernofsson M, Strekerud F, Toss H, Abildgaard U, Wallentin L, Siegbahn A. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost 1998; 79: 491-4.
10. Seljeflot I, Hurlen M, Arnesen H. Increased levels of soluble tissue factor during long-term treatment with warfarin in patients after an acute myocardial infarction. J Thromb Haemost 2004; 2: 726-30.
11. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-52.
12. Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000; 12(Suppl. F):27F-32.
13. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003; 109(Suppl. 1):S9-15.
14. Gustafsson D. Oral direct thrombin inhibitors in clinical development. J Intern Med 2003; 254: 322-34.
15. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999; 94: 187-97.
16. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P, Bylock A. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003; 362: 789-97.
17. Larsson M, Ahnoff M, Abrahamsson A, Logren U, Fakt C, Ohrman I, Persson BA. Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran, and the intermediate metabolites, in biological samples by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 783: 335-47.
18. Larsson M, Logren U, Ahnoff M, Lindmark B, Abrahamsson P, Svennberg H, Persson BA. Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 766: 47-55.
19. Eriksson UG, Bredberg U, Gislen K, Johansson LC, Frison L, Ahnoff M, Gustafsson D. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003; 59: 35-13.
20. Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003; 107: 2884-8.
21. Fager G, Cullberg M, Eriksson-Lepkowska M, Frison L, Eriksson UG. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. Eur J Clin Pharmacol 2003; 59: 283-9.
22. Soncini M, Gasparini P, Lorena M, Motta A, Cimminiello C. Prognostic significance of markers of thrombin generation in the acute and chronic phases of non cardioembolic ischemic stroke. Minerva Cardioangiol 2000; 48: 349-56.
23. Flather MD, Weitz JI, Yusuf S, Pogue J, Sussex B, Campeau J, Gill J, Schuld R, Joyner CD, Morris AL, Lai C, Theroux P, Marquis JF, Chan YK, Venkatesh G, Jessel A. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic+ + Syndromes. Eur Heart J 2000; 21: 1473-81.
24. Linder R, Oldgren J, Egberg N, Grip L, Larson G, Siegbahn A, Wallentin L. The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease. Eur Heart J 1999; 20: 506-18.
25. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-9.
26. Mann KG. Thrombin formation. Chest 2003; 124: 4S-10S.
27. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
28. Sarich TC, Wolzt M, Eriksson UG, Mattsson C, Schmidt A, Elg S, Andersson M, Wollbratt M, Fager G, Gustafsson D. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol 2003; 41: 557-64.